Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates - Concepedia

Concepedia

Publication | Closed Access

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody–drug conjugates

33

Citations

32

References

2012

Year

Diego A. Gianolio, Cécile Rouleau, William E. Bauta, Dennis Lovett, William R. Cantrell, Antonio Recio, Paul Wolstenholme-Hogg, Michelle Busch, Peng Pan, James E. Stefano,

Cancer Chemotherapy and Pharmacology

Tumor BiologyNovel Antibody–drug ConjugatesDrug TargetingOncologyDolastatin 15MedicineImmunologyHer2-positive CancerImmunotherapeuticsTumor TargetingAnti-cancer AgentCancer TreatmentImmunotherapyPharmacologyCancer Research

References

	Year	Citations

Page 1

Page 1